Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
63.95
+2.84 (4.65%)
At close: Jul 17, 2026, 4:00 PM EDT
64.53
+0.58 (0.91%)
After-hours: Jul 17, 2026, 7:19 PM EDT
KNSA Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, KNSA stock has a consensus rating of "Strong Buy" and an average price target of $66. The average 1-year stock price forecast is 3.21% higher than the current stock price, while the lowest is $57 (-10.87%) and the highest is $78 (+21.97%).
Price Target: $66 (+3.21%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for KNSA stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $57 → $74 | Buy | Reiterates | $57 → $74 | +15.72% | Jul 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $59 → $72 | Buy | Maintains | $59 → $72 | +12.59% | Jun 29, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $68 → $72 | Buy | Maintains | $68 → $72 | +12.59% | May 4, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $62 → $64 | Buy | Reiterates | $62 → $64 | +0.08% | Apr 29, 2026 |
| Citi | Citi | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | -6.18% | Apr 29, 2026 |
Financial Forecast
Revenue This Year
940.13M
from 677.56M
Increased by 38.75%
Revenue Next Year
1.13B
from 940.13M
Increased by 20.61%
EPS This Year
1.16
from 0.75
Increased by 54.67%
EPS Next Year
1.70
from 1.16
Increased by 46.77%
EPS and Forward PE are based on non-GAAP adjusted numbers.